Skip to content

Clinical trials

Thrombosis trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Thrombosis Phase: Not applicable Clear all

198 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20042
20053
20063
20074
20087
20095
201010
20115
20129
201310
20148
20158
20168
201715
20187
201912
20208
202114
202212
202314
20247
202515
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed115
Unknown status33
Recruiting20
Terminated13
Not yet recruiting7
Withdrawn6
Active, not recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Edinburgh6
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital4
University Hospital, Ghent4
Assistance Publique - Hôpitaux de Paris3
Harokopio University3
University Hospital, Grenoble3
University of Sao Paulo General Hospital3
Brigham and Women's Hospital2
Centre Hospitalier Universitaire, Amiens2
Centre hospitalier de l'Université de Montréal (CHUM)2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Thrombosis198
Venous Thrombosis17
Pulmonary Embolism14
Inflammation12
Hemorrhage10
Ischemic Stroke10
Stroke9
Atrial Fibrillation8
Cardiovascular Diseases7
Embolism6

Trials

Showing 51 to 75 of 198. Each trial links to its page on Pharma Observatory.

98 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.